<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-002978
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050201
<FILING-DATE>20050202
<DATE-OF-FILING-DATE-CHANGE>20050201
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>8731
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05567305
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v012078_6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD>
<BODY><DIV>
<DIV align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington, D.C. 20549</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><STRONG>FORM 6-K</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF FOREIGN ISSUER<BR></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule 13a-16 or 15d-16 of<BR></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Securities Exchange Act of 1934</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For the month of February 2005</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Commission File Number 000-5112</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida Limited<BR></STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation of registrant&#146;s name into English) </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12 BGC Centre<BR></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The Esplanade<BR></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA 6000<BR></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, pSivida Limited, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: February 2, 2005</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff border=0>

<TR vAlign=top bgColor=#ffffff>
<TD width="50%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD width="1%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD width="49%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD colSpan=2><FONT face="Times New Roman" size=2>pSivida Limited</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman" size=2>By:&nbsp;&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman" size=2>/s/&nbsp;Aaron Finlay</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD colSpan=2><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
<TD align=left>
<HR align=left width="80%" color=#000000 noShade SIZE=2>

<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron Finlay</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><EM>Chief Financial Officer and Company Secretary</EM></FONT></DIV></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD colSpan=2><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman" size=2></FONT></TD></TR></TABLE></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=black noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT INDEX</U></EM></STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">

<TR>
<TD vAlign=top align=left width="15%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT 99.1:</STRONG></FONT></DIV></TD>
<TD vAlign=top align=left width="62%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida to Present at the Brean Murray &amp; Co. Annual Institutional Investor Conference</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=left width="15%">&nbsp;</TD>
<TD vAlign=top align=left width="62%">&nbsp;</TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV valign="top"></DIV></FONT></DIV>
<DIV valign="top"></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v012078_99-1.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD>
<BODY><DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left>&nbsp;</DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=right><img src="mx1x1.jpg" width="248" height="79"></DIV>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>

<TR bgColor=#ffffff>
<TD width="50%">&nbsp;<FONT size=2><FONT face=Arial><STRONG>ASX/MEDIA RELEASE</STRONG>&nbsp;</FONT></FONT></TD>
<TD width="50%"><div align="right">&nbsp;<STRONG><FONT face=Arial size=2>2<SUP>nd</SUP> February 2005</FONT></STRONG></div></TD></TR></TABLE></DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><br>
  </DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Arial"><STRONG>pSivida to Present at the Brean Murray &amp; Co.<BR>Annual Institutional Investor Conference </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;
<DIV>
<HR align=center width="100%" color=#000000 noShade SIZE=1>
</DIV></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">Global nanotechnology company pSivida Limited (<STRONG>NASDAQ:PSDV, ASX:PSD, Xetra:PSI</STRONG>), is pleased to announce that Dr Roger Aston, Director Strategy will be presenting at the Brean Murray &amp; Co. Annual Institutional Investor Conference on Wednesday 2<SUP>nd</SUP> February at 11.15am US Eastern Time. The conference will be held at The New York Palace Hotel, New York, NY.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">A
    link to the live web cast and recording of pSivida&#146;s presentation will be available on pSivida&#146;s website <U>http://www.psivida.com/News/Presentations.asp</U></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>-ENDS-</STRONG></FONT></DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Released by:</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>

<TR bgColor=#ffffff>
<TD width="50%">&nbsp;<FONT size=2><STRONG>In Australia:<BR></STRONG>Josh Mann<BR>Investor Relations<BR>pSivida Limited<BR>Tel: + 61 8 9226 5099<BR><U>joshuamann@psivida.com</U></FONT></TD>
<TD width="50%"><FONT size=2><STRONG>In US:<BR></STRONG>Beverly Jedynak<BR>President<BR>Martin E. Janis &amp; Company, Inc.<BR>Tel: 312-943-1100 ext. 12<BR><U>bjedynak@janispr.com</U></FONT></TD></TR></TABLE></DIV>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left>
    <table width="50%" border="0" cellspacing="0" cellpadding="0">
      <tr valign="top">
        <td width="50%">
          <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Ticker
            Symbols<br>
            </STRONG>Australian Stock Exchange<br>
            NASDAQ<br>
            Frankfurt Stock Exchange (Xetra) </FONT></DIV>
  </td>
        <td><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">: PSD<br>
          : PSDV<br>
          : PSI </FONT></td>
      </tr>
    </table>

  </DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;
    &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></DIV>
  <DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;
    &nbsp;&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=black noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>NOTES TO EDITORS:</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>pSivida Limited</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company&#146;s focus is the development and commercialisation of a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon&#153;. As a new and exciting biocompatible and biodegradable material, BioSilicon offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnostics applications are being developed through its subsidiary AION Diagnostics Limited. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida owns the intellectual property rights to BioSilicon, royalty free for use in or on humans and animals. The IP portfolio consists of 24 patent families, 26 granted patents and over 80 patent applications. The core patent, which recognises BioSilicon as a biomaterial was granted in the UK in 2000 and in the US in 2001. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida is listed on NASDAQ (<STRONG>PSDV</STRONG>), the Australian Stock Exchange (<STRONG>PSD</STRONG>) and in Germany on the Frankfurt Stock Exchange on the XETRA system (<STRONG>German</STRONG>&nbsp;<STRONG>Symbol: PSI. Securities Code (WKN) 358705</STRONG>). pSivida&#146;s shares also trade in the United Kingdom on the OFEX International Market Service (IMS) under the ticker symbol <STRONG>PSD</STRONG>.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">The Company&#146;s strategic partner and largest shareholder is the QinetiQ group, the largest science and technology company in Europe. QinetiQ is the former UK government Defence Evaluation Research Agency and was instrumental in discovering BioSilicon. pSivida enjoys a strong relationship with QinetiQ having access to its cutting edge research and development facilities. For more information on QinetiQ visit <U>www.qinetiq.com</U>.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">pSivida has a strong management team with a powerful blend of international experience in biotechnology commercialization, the pharmaceutical industry, licensing and capital markets:</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Mr Gavin Rezos,</STRONG>&nbsp;<STRONG>Managing Director -</STRONG> a former Investment Banking Director of the HSBC Group.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Dr Roger Brimblecombe,</STRONG>&nbsp;<STRONG>Non Executive Chairman </STRONG>- former Chairman of SmithKline &amp; French Research and Chairman of MVM Ventures.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Dr Roger Aston, Director Strategy</STRONG> - former CEO PepTech Ltd and Director of Cambridge Antibody Technology Ltd (UK).</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Professor Leigh Canham, Chief Scientific Officer </STRONG>- a DERA fellow and the world&#146;s foremost authority on porous silicon and the inventor of BioSilicon&#153;. </FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">
`
<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial"><STRONG>Dr Anna Kluczewska, Managing Director, AION Diagnostics</STRONG> - a former Global Product Manager with Baxter Healthcare Inc, based in Munich and Vienna.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">For more information visit <U>www.psivida.com</U></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">This document contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors including: our failure to develop applications for BioSilicon due to regulatory, scientific or other issues. Other reasons are contained in cautionary statements in the Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item&nbsp;3.D,
"Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial">&nbsp;</FONT></DIV>
<DIV valign="top"></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mx1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mx1x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!/`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBD)`Z
MG_(H;MN`M%-WCGKP,]#_`)_/%(74=_\`.,_3Z\U/-'NOOT^_8'I_5_R'T4W<
MI&0<C_#]*0R*`22<#&<`D\G&0!R<=P,GVZ9:E%I---/5-.Z:76ZT'9]GVV>_
M85B1@CIGG_.::[L$+*`3C(!!`ZXY()_G7!?$CXJ_#SX1>%=2\;?$SQ;HO@OP
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MF1M)?3-*\7E0N(?*EE81(Y<$#Y+\`_\`!5O]EKX@?%#PI\*+>Y\?^%-;\>7S
MZ9X)UKQ[\/O$'@_POXFU#!6WMM,UG68K>"9[N<Q06ICWQSRSPQ))NEC+=U\&
M_P#@G[\%OAU=Z=XQ\>P7WQU^,(LDBUGXJ_%>1?$NOWMRS1SW']G6=T'TK0M/
M:[5IHM+TVTBM(BS%$4LQKY/_`."@6C>#OC_^TK^Q)^QWX5TBUN?$^E?%_1_V
MB?B+J&B6]E#<_#[X6?#*TU0);7LT*I/IL/C/4]0ALK")0HDGT^&2/;)Y+#OP
M='+:U2=":Q-64:5>I4Q4*L:=&DJ5-U(OV,J<I23<=I5(2ES1II1DUS?"\79_
MXC91E^&S[#3X;RZ%7-N'\OPG"F(P6+S;-LTJ9KFV#P%3"3S6CC,!A,'BY4,5
M4J..%R[,,/@EA:N*GB<70C45/]H87>1-S@*2S8`!&$S\@.23N"X#=!NS@`<5
M+4%OGREW`@GG!;=C<`Q7/L21^''&*GKRFTW=*RZ+7]=3]D5UOOUV>O:ZLM`H
MHHI`%%)N&<9YSCO2;AG'IUXX_P`^_3WJ>:-VN976ZNK[7VWV"S[;[#J*0,#T
M/Z']:,_7TZ'_``_7I333V:?]+;ONOO`6BFAU()YX.#D&G=:%)2U337=.ZV3T
M[Z-?>`444A(`R>@_'^5,!:*9YB^_3/0^N/SI]`?U^GYIKY!1132P'_UJ-Q-I
M*[T2'44W<,A><D9!QQW[_A3J`33O9WL[/R=D[?<T%%%%`PHHHH`*B<`L,CL!
M]02>/KQQUSGMCF6BIE'F25VO>B]+IOE:DE=-.S:5^ZNGHP[^:M\GN?/7Q`\;
M_$+P=?W=XEIX7'AP3*NG&_OQ:WUZT=ND\ULBEB6N6"3&)%0LR["%+8%=A\./
MB1I_Q`TVXGMXC9:G9.L>HZ=(Q9H2X8Q31DX::"7`"N%R'#HZJR,`[XL0%_#4
M#[-29XM7MG4Z-I-EK5ZI:*Z7=]FU"-XDA;Y%ED4!PY2,-MD8U\S?"2>72_C-
M)I\/V^*UU&WU&TGAU&!+*\<-8G6H);FQB)@@<2Q2/$D0"".8%57=A?XTXHX]
MXJ\+_'KA#AR?$.<9WP9QQFF7Y-C,JSNK@\3'`YEQ)6KT\NQF58ZTL=@Z6%QL
M8X9X%TJ>%J896<ZDU!K[?"Y=@<TX>Q.)6%H8?'8"E4J4ZN&C*#E"ARN:K1^"
M;G'>5^92DI:)6?L_BWXH>._";ZG<W'@-9-"L+IX(=6^W2B.:V,OE07$D:6[F
M(2DKD'*J2.6R#7`V_P"TOJM]-#9VGA.WEN;J5+>WABU"Z>2::5Q'%'&JVARS
M.0!VS@\#(K<^,/QB^'=_-XQ^"]CXCT^]^)-IX"'CO4/#=G,MQ>Z;X9M/%?AK
M1!?ZD(2ZV?VG4=7MH+**X,<ETJW$L*,MO(1\P?#=2GCOP:A()3Q'H2$@Y&5O
M8E.#[$8K\@^D-X@>,GA?XO\`"G!.1>*F?2RCB_"9+F:^NY'PE5K99#.>),RR
M>6%PLED,8UZ&&I82-3#SQ"G5ES<M6<^53??POA^'L]RC&9@\!@JU7`8G&X6J
M\/BL1-5*N!H4*E6G5<*S5.<)U5&LHVE&4HVO[R7?>+?V0_AY^TW\1]!^(_[0
M_A#Q?J(\!ZCI^M^$/!&L^,[J\^&\NII:7=I]JNO!D-M;V5W/8!4NE>_>Y83W
M`9)%C,D3>R^(_BW8^&=9A\#>`M)T.U@TD'3Y+BY:#2O#^CI8H`=.M(H4CMTA
MMHQY>R()"DV+>,>8=M?0'B*\.FZ#K.I*!NT_1]1O$R0!YEMITLZ9)/'^K//'
MYXKX&^&MK+.E[<SCQ)/<3ZA;VDUSIVAZ=K-O/@"61[R?4%<Q7$LUV[S>0`&B
MVL[M(&"_KOCGXC<?\"TO#+PMR3C'/,PSG/JN=8_..+<9A\EAG-3),MQ4<14P
M6"P^%PN6Y5@IXVKB7@UBZ%"C6P^&P4$Y8C$2G5GX/"O#'#<\;Q'Q'2R/+\'6
MQ<L&\73PM*<98RO#"0P]&IC<1*<\1BO84<-2ITZ=64J<82M"--15O>O'7QF\
M5_"OX::IXM\4>'H=?\6ZEJ5EH/PW\'^%R;J]\:>)];C$'A_1;<QM(85O;UA)
M=WLNRWTW2XKO4+MXX+61QPO[*?[,EW\*M3\=_&CXH3V7B?\`:/\`C;J$6N_$
MSQ-;!I;#0+5(8VTCX<>#)ILW%MX.\*6YCL[.,&(:A<6SZE,GFS[G^K6\.V-Q
MJUGK]S%'<WNFVAM=*%P@>/2S*DT5W/91!0L-[>6\HMKFY&91;A[>%HXI+E+K
MKZ_KSA_!U,FR/!94\QS',ZU&A".(S+-<1+%9EBVY>T;Q=?EI^UFI\T6[+W80
MBE:$7+X3,,JH9GGM'.L72H<N6SK/)<'3IJ.'R_$U:,L-B<?2CS-/$U,-4J8:
ME*2;H4JN(Y)?OYI-0`*,9&><'KR.GX"G9'K7F7Q?^+/@KX'?#KQ=\5OB)?S:
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M[E6[:71PSQ)P[QE2C7X6S[)\_P`/];I8*KBLIQ]#'8>A7JSIP5.M4P\ZGLYI
M5(R<96?(U.UFK\;XP^-O@_PC>W.G/+<:KJ-K)BYM=-19?L[[F7RYKAF6".0;
M&8Q%_,``!7YA6)H'[0_@S6+E+:]COM$:62.&.6^1#;F6638B23P-(D!;/!D*
MH?7M7RK\+O"EAXZ\;1:5KMY,;1K74+^Y83*MU?7%LULJ1&9UD8LYG,DK`;W1
M`&92&*^M?%3X&0Z9;6&H>!=.U"\:XN3:WVF0R_:6A9T)MKR%BHD6%6B:.?<9
M.948``,!_G!E/CA])SC7A[.?%S@_+.&L1P-D^=RP/^I>'P5/,,]Q6&C4PU.M
M1HSAA9YE6E2AC*-3$5Z56A4:]I5HX>=&DZ1^T8C(N%<OQ-#*,95Q3QV(H1JQ
MQTIRA0ISO):WGR)2E3ER*2:M9.[>OV7'/%+%%-`ZR1S(KHZ,&5D=258$<,#G
M(([<^U>"?$[XV7'P_P#$L>@QZ+%J"/IEMJ!G>[D@8&XGO8?*V+$XQBS)#%AC
M=T`KI/@WH_B;0/"2Z3XG5A/;WMP^GK+=)=3Q:=-'%*EO+(CMM%O<O=)"C$,M
MOY*[0,A<WQ_XF^%6E:]'9^,[&VN=:>QMY5>;3;F[;[$TEPD8$T43J%#B<;2<
MC+9YK^G^.N*^)<X\',CXGRWBK+O`S/LUGD5?&8OCB.'PM+)IUXU/KF1UX9GA
M)15>M-*IAY2PU*I5P\%5E"ES2B?*Y?A,+0SO$X6O@Z^>X:A&MR4\#9RJJ#I.
M-6,HS?NV;B_>:C*Z]/3?#.LOKN@Z+K+1K;G5M*L-1:W1V<1->VT-P8P[<OL$
MNW.`#@'`S72C^I_F0/Y?X5XI\1/C!\/?@C\&M9^,OBF:\L?AOX-\,V.O:E=:
M+H^H:O=6'AYOL4*W<.DZ9!=:A-;V<$\<UPEO;RF"TAFG8+'"37C/[+/[?'[-
M?[8VI>+]'^!7BO5/$6I>!]/T75?$5IJOA;Q'X9EM++Q!<WMKILL:^(--T\W0
M:?3[F.=;<R&W=$68(98]W[QPY0QU?A_*\54Q"S=TLIRV6-SO"TU]2S"M4PN'
M4\PI.E"%.G2QM1_6*4%&$53Q%'E6O*OA<RXCX>P'$-#AW%9SEF"SS-7B*N59
M#B<=AJ6:8JA0]JZDL+@IU%B,1&E&A7=:5*%10]C4NVHR:^TLCU%>4?'CXDGX
M-_!'XO\`Q<731K)^%_PR\<_$)=(\XV_]JGP;X9U/Q"-.$X#&(WO]G?9A)M.P
MR!B,`UX#^U+^WS^S7^QUJO@[1OCIXMU+P]J'CO2]9U7P[;:7X7\0^))+JRT.
MZLK/49;@:#IVH?8@)M0MDMOM8A^UD7'V8R?9I_+[BR^/WP.^+?[+NM?']KA]
M;^`6M_#KQEXGUJZUG0=3M5U'P!HMOK=IXIDO-`O;6'4I+.6PTK4PUL]F)+NS
M=61&CG4GWHX:M#ZO7JX6K/"U:D5&2C**KI32G2I2Y6I3;4H+EO:2?:QY>*XH
MR/$U>(,BR_B?)<-Q)DV68C$X[#/%X6OB\AC/#*>&S+,\O=3VM+"TG6H8F3KP
MA3J490;ERU$?F[_P3S_X*Y:K^W#\=-6^#>H?!S3_```NG_#SQ%X\@UFS\47&
MN/+%H6M^%M'2REMI=,L?+DN#XE64E&E2/[*5$C;AC]OAT'T%?D7^Q-^T9_P3
M4^*WQ?O?"W[(GAOP]HWQ23P3JVMW\^E?#3Q%X/F_X0^VUGP_;ZQ&^KZKI%C9
MRPR:KJ&C/):),\TLH61%/E$K^E/Q1^*W@'X+^!=>^(_Q-\2Z=X2\&>%[![_6
M-;U2X6&VMX(\A50$[YIYY-D-O;0J\T\SK%&C,<5TYK2IK'1CALMQ.`C4HTE'
M"UG.=24K-.HE/WE[1VLDVFT[-GROA9FF-EP/]?XB\0^'O$"OAL9F-3%<69-/
M+\/E,,-3]C56%G4P:IX6,\#"<E5FXTW:24TG%R?I#ML)8D8"9QCDD;CC\N@X
M/]/RK^%/_!7C]EOXQ?&WP[\!?"3>-#XZ\3>+=3\&6$5]X7U"TTPZII;7HNVD
MU"2(0K`OV&?RY0Q\SR\C(89T?@I_P5\_8D^.WCV#X=^&_B->>'=>ORPT2;QQ
MH.J^$]*UN595ACL[#4]9MK2T.H7+./L>G32QWET`WDPOL;'\MW[`#))_P5(^
M#)CDRI^/GC!\=F5XO%FQ@`>=Q&]3T*X8$UZ66Y)*K1S1YCAL30JX7`_6<,Y0
ME32ER5)1YHRA[T6J:UO&UW[R:1^9>)?CHLJSKPJH^'N?\,Y_E7%_&L>&\_KX
M:OA\WC0H3Q624I*C7PN(:PE>-/,IRBZD9K6G+E::O_>FC`_AD9P1T)'(;D9]
M.V0/2I:Q]6U;3=#TR\U75KZVT_3=/MI[J^O[V>*VM;6T@$CRW%Q/,R1Q1HJ9
M9W90!R3@,1^3OCC_`(+;?L&>!_$=_P"&X?'VN^,9-*N6M;S6/!_A76]:\/-(
MA&Y]/UJ"T^PZO`H)'GZ7-=P[E:+>)5*#Q,/@L3C%)X7#UJ_(H\WLJ4IJ-TK<
MS2M'F=[7LW9V70_>.(>-.$^$(X>?%'$F1\/PQC?U5YOF>#R^5?E2YE1AB:E.
M5;V:<>>4$^5./-:ZO^O5%?)?[,O[;G[.?[76EWFH?!#Q]8^([O37*:MX=O(;
MC1?%&E`8"RWWA_5H[35(K:3)\F[-M]EF"EHI7!!/UDN22?H,>A'7V_*L:M*K
M0J.E6ISI5(Z.%2+C)/>S3LT[>72Q[.59MEF>8"AFF39A@\TR[%1Y\/CL!B:.
M*PM:'2=*O0G.G.+NK2C)K5=QU%%%9GH!11368*,G)]A0)NRN^GS_``6IPWQ*
MT^'4?!VJQS0V5PMLD=^(M0BU&:U(L9!<R%XM)9=0D*P1RLBVP=RX`*.NX5\*
M6NIIX;\=:9K-I<6>FV]QB&*ZTZRU=++2Y[JRN]%DG6+7[>.\F-B;J+5)HI%D
MC>/S-K)$H2IOV_/VUY_V>O#WAWX3_!S38?'_`.UI\:[V/PG\%_AO8/;:C=Z?
MJ>K6]Q##X^\5Z2LR72>$/#TJM<S9$"ZG/;20&YLM+MM9U?2O8O\`A4WQ:\9_
M#WP<_P`1_%^@Q_$1_#^DS^/M&T:SN[CP+'XO^QQKK+^%+V^M'UZUTMKGS5ME
MNWG:2#&(8X]L:_R;])GP=XIX@?#/B7P1ESS'BCA?,LHS++\MPN'RR./QF(X?
MS"68X+%RQ6.S;+I+`TJM2="O"%''8B;A!8>A)P=O3X,X[X?Q.=9[P7/$593P
M&#C_`&OBU3Q4<NP,\RII0RZICJ6%KTHYF\.H8MX>%15\/AZT*U10C4BW\S_`
MC]A_PQ^RC\&/B9XLU[Q%>?%']H7XJ6]IJ?Q<^,FMSW%QJ/B.^N=?M=3;2=&2
MXVKIWABQNYPFGVT$,$ES#!:FYCCBM;"RL;WPU9CXY\&.PW9\0Z"22?XOMT)8
M=>3CMDX[8Y->I>*O"7QB\->$M1L]6UM=0\)VL$,5XD6H172_9DEACM42.^M?
MMV%G-N-D+PH0!A<Y%>*^&EU:;7M#CT)O+U5M1T\:8Q,+;+UKA!;,6EW0#:^W
ME]R@C)4D8K^'?I+^('$'&7C-X><2Y]P/Q)PIG&79/PQ1K<.YQ3PWU[%5<'Q3
MF>+BLF]A4E3KX/$3G]2P3E##RE6I5%.C!--_HG`7">1<(\)XSA[(ZN"AE_UC
M'U:-7"SG*FZN)HQJ8K%8VK)RJ5<;B:]1XC&XK$3J5Z]6M*O7J5*LYL_0KXMZ
M[9:+X`\2-<7$<<NHZ3>:381EU+7%YJ-LUA&D:##N(EG,\Q3+)!%)*1L5B/E;
MX3:';7NIZ19WEGHU[>:CJ[WYBO;#Q4FHVUK`1($2[LHO[$C"V]K-<Q_:9$$C
M/$)FQ@#J;GX._%[QC/:7'BWQ%:JL!5XX]0O&U".&7YD:6+3K"UCTW<4*==OF
M+N261>&'T_X-\+WGAK3K:UU'7[SQ%=K&HDNKF*WMK>+;'M$5A:6J)';VR;<*
MKM/*1UE`^6OZF_U1XV\=O%_)>,^)^`\[X$X.X4RVE@<II<1X3)L7B,R4\?\`
M7\QGB</_`&O2QN"QF*GR87!RH9=F>$H48/$8JK=_5:GC2Q6`R#)JN$PV94<=
MCL96E.K]3G6@J+C25.E:K&FX3A%^]*//!\S?*];KKXD.WE3G/&X!<<#J!QD=
M.,@\\GO8I,<YR1[=O_K?Y]:6O[JA#DNDK+1)*R5DY/9)6;<FW^2U/@VV[?\`
M!_7T_IW/SZ_X*H(I_P""?7[5#$<M\-I4)W,/D;6-(1AP?ERKL"PPV#UX&/YD
M/^"-G[''P=_;"^)GQ?L_CCI^N>(O"WPZT#PCKEKX2L=<U30=(U?6-8U37["*
M\UR71YK2^D&EV]G=1VD<%U;-C4+@,YCE=6_IQ_X*H_\`*/C]JC_LG$G_`*>M
M&K\1/^#<K'_"ROVJ@3C=X.^&X'K_`,C!XO/ISC&3T^M?;9/B*N&X9SNO1JU*
M56GB,)R5*<Y0G!3JT(RY)Q:<;IN]FKG\7^+>3Y3GWTHO!K*<ZRW!9MEF+X8S
MN6*R[,,/3Q>"Q7L:'$=>G'$X:K&=*M!5J-"I*%2,HR]E%23BM/SO_P""L?[,
M7@+]CS]K"R\'_!.QOO"OA#7?ASX3^(_AS2WU;5-4N_#.H76K^(O#THL=3U&X
MN=4DC34/"<NJ64TEW/<6L]P1'<^7%"$_M#_9W\8_\+R_9B^"_C[6[;]]\5O@
MQX"\4:W!D@FY\5^$--U#4H5="5!\Z^F1)-Q7:$(.P*5_E3_X.$7C_P"&VO`"
MJ5=K?]F3P."@?YD9OB1\7BC,@#,,#:PR,,A9@V(V!_I?_85UG3_#_P"P;^R3
MJ>KW=O8Z=:_LV?!9[F[N':*&'?X"\/QH267)\UV54&`Q)`VY(W<7&=7`5^#L
M#B<_GA_J#PF.68XK,:L%AIY?6PLWC_KE2M^Z]@Z,(K$3KU(QE3=K349<N?T?
M,+3R+Z0/CIP]D&%HY9D^&Q."J8/*LOP\:&&P]6AF:AA*6#PE!*-*G16,K0IQ
MHTXTX*<.5122?FGC;X=>*OAGJL-];O='38;AI]-U_3TF18%BE=HH;R91&UI=
MA`B21R,T%VC,O[Y!Y9]5\!_M$3PO%IWCF)[K$D:IK6GI&C1(610;^S,@8HB$
M/)-:[N!EK<+P?H31/'/@GX@7&I^']+O(M7$$*->VUU9SK;7$$DDJ.$CO8XQ<
MHAA(8QQLD0DMV8G>`?F7X[?"_1O!]KIGB#PQ"ME:W5ZUA=Z:KR20P32Q3W,$
MUE'-(3%'(872>%6V1962)=I9*_R<XEX`XE\$,+F_C)]'#C_"YSX<8?%5<7GW
M#4LP6/RZC[+$QP&*7L^>>"SC#X.6(]DZB=#-L%1ES4JM>$&W_I%A<QHY\Z.2
M<29<Z.9SA&.%Q4H*G._+[2*=U[2FY<C=K\DI)MZ^Z?:5C=65_;6U_83Q7-K=
MVZSVT\+AXI8I$61)$9<*=P*G(Z9VYP0!\,?M*G'Q'M"`,CPUI1Z#JM]K@&>.
M0!Q@Y![@U[%^S3K%U?\`A75].GE:>+2-45;)FW?N;:\MDE>V0G)\M;J.XE6-
MG;REN5B4[8U+>.?M+?\`)1[3_L6=,_\`2[7*^T^DAQS2\2?HF<-<<4<+]0CQ
M#GG#>)KX)3E4CAL90K9S@\QH1J-1=6E3S#"XE4JCC%U*:A.48S<DN+AK`SRW
MBZM@)RYWAZ&)A?\`FA*.'J4[]+\DXW6J3NEL?0][X)TSXE?L]7?P\UJ&*XTO
MQY\(I_"-_!.H>*6T\2^$'TF=)5*N"IBO7;`!/0`'(4_R)_\`!&?QOKG[.O\`
MP40D^"GC..:SOO'&G_$3X(^(K(>8([3QIX,EG\0V\LQG6&=4&H>"-6TFU$X0
MM/K,:&'S9(T7^R/X?[F\`^"B"?\`D4_#P&.HQI%H,Y_#N.^.>_\`&5^WC?7O
M['?_``5YU3XM6EN\>E6/Q1^%7QZM8[9)(YM3T'Q$/#UWX[6)'CGW_P!K:O:^
M-M)D6+?M#3O$5=!&G^A?@_?$\#97DR@N7$\&</UZ,;I)XBAE&$I1BHV:;3JQ
MG>-I?NU:]DU_"OTI80X:XG\*/%6,I0EPGXD0RG-)QM&3R3.J]6IBJE?$<T'&
MG"E@,1AXJK/V3ECYQFU[7DJL_P""TGQ+O_CI_P`%!;SX7:!$\Q^&>C>!_@OX
M?MI"?(O/%WB22W\3WD\!C,LA\W4_&=CHD@4"02Z0\:1>8'+_`-.OQB^%&C?!
M+_@F3\7/@_HW[W2_AS^QI\1/!L$SEBUY_8?PCUJQN+V4,<F2_N(YKR;(`,DS
M':``!_+]^Q]X;L?VV_\`@K]>^,M1F_M?PB/CA\2?C_)<!':&;PMX&UV^USX?
M#,9A8V:ZM_P@]B'F90T)6.6*4,R2?UM_MM`I^QE^U>,[B/V;_C9AN02P^&_B
M0<+SW&<=.U?79[66%7#N60O">&I8:=2*O%*K6G!N36EY*3G+FT:Y]7J[?)^!
MF$?$B^D!XIXN,:\.*LXX@RC*YU/9U92RC+,-B:\:=.3YFL/4H8K`T)QYO95?
MJ<$DXTHM?RM?\&_BK_PW-XHX&3^S?\0B3WS'X]^&&SGJ,8!(!PQ`+9(S7WI_
MP<9^,=0L?AQ^S'\.[>\N+?3O%'C;Q]XOU*WBDECAO6\$:/X<TK3DNEC*I<Q0
M/XYFNXH;GS8A=1).%,]M"\7P9_P;]_\`)\WB?_LV[XB_^I]\,:^N_P#@Y$`6
M3]CHG<"4^.8'4*?WGP<#(>.O(;KD`$8YS7N5*2J<<8*G965&E-+W;?N\-5J;
M/2UU=K=]-3\GX<QV(P/T).+*N'JRI5*O$,\#*5YJ]#'\39#@\13]QI_O:%6=
M*S]QJ;C/W')'5?\`!-[_`()/?LL_&W]BCP=\4/C5X1U3Q1\0/BXOB;68O$&G
M^)O$&D2>$M(@U[6-$T"STBSLKNWTJ>X@@TN+5+V;4;"^)O+IK,$VL'ER?CC_
M`,$W=*ET+_@I=^S]H@D^U1Z'\8M7T*.\V+&]S%H^B^);!9WCCDDBCDN!`LSJ
MCR8D9QYA(!/];'_!)YHW_P""=_[,I2175?"&NY"X(WQ>./%*O'D$\QO&RMD9
MR,$`@@_R@?\`!/HAO^"I/P<!RN/C_P"-,=P<Q>+>1TZ?0]0>*Y\%C\7BJ?%L
M9XFM6IPIU?9TZE6I*-*E%UX2C3C.7[N*I\L7"-DXJ"<7RQ2[>/>#>%N&Z7T2
MLQR+(<LRO,,TS3A;^U,9@\%AL+C,UE5J\(8MXC,L7AX4GC<0J]2K-5L5[2I"
M5:LXRBIU%+^J+_@J1^SS^T7^U)^SY9_!G]G_`%7P]HTGB#QII=[\1+GQ#XAO
MM`AU'P9I-KJ%S%HD<^GV-_-/!J7B`:7)JED8X[>\T^RNK.Y\V&[,,GYV_LT?
M\$,/@WX/^$7B75?VS+U+WXAW5QJDD.H>$?'-[I?A#P-H5O;^5I^H6][)9Z8F
MI:I+*)-2O3JMLVGPLR6:6\T4#SR_IW_P4/\`V]/!G["OPFB\5:AI]MXJ^(OB
MZ_N-#^&_@,ZC'93:WJ$$*2ZCKFH.D<ES;>&_#:W=@^K7*1F26XU#3-,M&^W:
ME9JWX)_`WX-?\%(/^"M]A=>-?C+\>]?^&O[-NHWKV[BUL)?#_AWQ3#!.UGJ^
MD^#?`GA]].7Q3I]D_P!IL6UGQGJEWI\=_"ZQW6M>5+'7EY5+-:661E'%4\FR
MQ8CF>81<EBL5)6YZ5.-&7M:RA'W>644G;DBY<LXK]D\4<-X;XKQ1C2EPAFWB
M[XF5<AAA*7!<ZN$K\,</Y=5I8>6'QV:SS&DLMRGVCK.M&I.>(K4O;+$SH47B
M,-5G\:?\$W9)OA+_`,%2/A-X:\+Z\FL:=IGQ<^(?PO.N:=,CV7BSPM)8^+_#
MJWK2VV8+NRU2*#3];MV#26Y>UTZ6%B(;=A_>$I!S@$=,D]SDCGWP`WN&!]S_
M``8_L->#[+X>?\%5OA3\/],NKB]T[P)^TEXP\&:?>W:1Q75[9>%KOQ3H=I=W
M$4*1PQ37,%C'-)'%&D:.Y5%"@"O[SD_B^H_]`2EQDU+'X":?-SY93DY\O(ZE
MZLVIRC9-.2=^5ZQOR]#E^A>ZRX%XUPU6F\/#!^(.9TJ6!5:5>C@%_9F4NIA<
M/.4FG3IU)27/%_O&G4;<IMCZ***^1/[%$W#&<\#ZU\W_`+5G[2WP]_9,^"_B
MSXT_$J_:WT/0+1;;2]-@\UM0\3^*-0$T7A_POI441W?;M9O5$)N9=MGIMFMU
MJFHR0Z?8W,T?T:<*K#/<9)`P-Q`S@D<#.3SQU&>!7X5?M#^$KW]MW_@J/\._
MV=O%]MJ9^`?[)'P]TGXW^+]*7=#IGBWX@Z_?:=<>&[74TE9H+W3Y+:YTJTA1
M8&:2RTWQKIYE07Q:'NP%"C6KMXAOZM0C*O75U&4Z5.SY(-JRG4=H1?1R32;T
M?P?'_$.;Y'D5.GP[AZ>)XFSW'83(.'HUH2GA<-FF82<7F.-2G!RP.486&)S3
M$P3?M:>#E0O%U%./JW_!.+]D_P"(<?B'QE^W+^UE'+K?[47QYM4DTK2-7^Q7
MUI\&_AM+,]QH7A?PW&8#+H]]?Z--I\&HVXG>72])M;+1HUAO+CQ-<:Q^OPC`
M4D*H9\&0\98@8R3W]!Z#C@<4D4:QJ`HP,`!1M"A5`50```!@#A0!SR,UF:WK
MNE>'M.OM7US4],T72-.A-Q?:IK%_;:7IUG`H+22W5]>R0VEO$JX)EFE1`<@]
M,USXFO5Q52<ZBB[I0ITHK]U3I125.C3C[S]G%:*+O?5ZMN_K<*\,9;PEDF%R
MC`SKU8T?:XG&YCC:L:N89EF&*G*OC\US'$\M/V^.QM:<ZM>M*,>6+C2@J=&G
M"$>`^-6/^%9>*%X!%K9%"!PQ&JV+#:2>2!\PZ#(..<"OSFT#QEH?A'Q?X"GU
MR\F:ZU+Q/I%IH^BZ?:W.K>(?$5_:R?:Y[/0-$L([C4M8GM[:"6YNFLH98;"T
MAGO;Z>ULK:>XBI^.OVZKG]INZUGX3?L9>%[?Q[HEKJ":=\1_VC?&5OJF@_!/
MP!IMM=127=YX?N);47/Q,\20?9YFL?#NE2V%I=3QQ^=?FTE\VH?@]X`\$?"S
MQ]9^+3KNN^/?%^I:QHO_``D'Q9\:HDGB!M(2]@>]T;P9HMM"ME\//!DCJ'?0
M-%MHKW4@P_X2"YU!EE9_\\/I5\(<.X7QF\/.-./.*,%P]D^6Y7PY@<#D>$E3
MQ/%>=9E@^)<PS"\<%.#PF39-0CC*$\PSS-ZN&IT\/S+`X7'XA.DOT+@3C&IQ
M!D>:X+@K#1SFC#'8B.*XDJTYKAO"TJF'IT*U/`XJ+IU<]Q]Z52%*CE;JX2A7
MBXXW&T'#E?ZF^%-0\2:Y;3ZCKVAKX;C>8C2]&FNH+[5(;54C"W.LW5K/+8PW
MTKK*!I^G27]K9J/^0O?M,5M>S52N.>,?0_IP?Y#M7)^&?%WAOQ(+L:!JUGJ;
M6D=O-="U9R8EN#*D;2*X!3S6AE"9R3Y;`X"@#KZ_OG`8_+LXPE#,LKQF#Q^!
MKN<L-C,!7HXK"UHT:LZ,U2Q%)U*<^2I2G2J<DWRU85(W4HNWANA5P[=*NJD:
M\;>T56/+4NTI)RCR4]XM.,N2/-!J25GJ4445Z`'Y^?\`!5'_`)1[_M4=?^2;
MR=.#_P`AK1NGO7\I7_!+O]H#]IC]FSQ1\;OB5\"/@2OQ^\):;X5\._\`"X_#
M-C<W%GX@TO2$UG6;CP_K.AMIT6IZL[07`UF*^2Q\+^(4^RF)[J*TA@68_P!6
MO_!5'_E'Q^U1_P!DXD_]/6C5^('_``;G1++\2OVJ`XRH\'_#C(.-K`^(/%X*
ML"<,I'\+`J2`2,J"/M,DJTZ/#F=5:V'I8JE'$87GH5G-4ZD95*,;.4)0E%IR
M4H24M)QBVFKI_P`5>,F6X[./I-^#N79;G6.X>QU?A;.I87.,MIX6KC,%6HTN
M(J\90I8W#XK#5:554GA\51JT9*KA:U:$94YRA4A^6WQZ^+7QJ_X*L?M@66I>
M#OAO]D\>^)=+T'P%X8\">'[^Y\11^$O"?AZ[NE>_\1ZU)I]J8=.M-3UW6]6U
M_6[W3M+TW3(;WR%A^T!I9_[JO!WPFT'PE\&?"GP6L4ED\.^#_`'AWX>V$K>4
MLZV'AO0[#1K.Z!W,OVM18Q7!D()-QN<#:5+=MH_@?PCH-U<:AHWAS1-,U"]Q
M]MO['2K&UO;SD,3<W4,"SSLS99FDD9BS%B<\UU*J%S@G&``"<@!1@`>G'7U/
M/7-?-<48G!<496LCQ>74%D[P6,R^O@I6K0Q.%Q]%8?$4:TIQNZ<J'/34=^6K
M4<I2<DX_M/A!X18KPTS;BWBC-.*<5Q3Q9QAF&'QV8YO4P='`0I+"UL1B*,*&
M'A.NXSG6Q,I5G[54.6EAX4,/15-\_P":MUI/C?X.^*%U#RY+.ZM7NXK+4XU\
MS2]3LY603)*\82/9<^7&9K1Y([JWEC4KN7RV:;Q1X_\`&_Q9?3-+>SAO&MKE
M9+?3M"LKORI+J=7A^USB2ZNY&,$9>)9&6*./S7[,S#]%KBSMKH.EQ!%-&6;*
M2I&ZL<Y!*NI!Y`(.-W'!J*WTK3K5O]&M8("<$^3$D);G')0+N&.BDD<@[<X(
M_P`]JWT,<WPL,TX7X=\8>),H\,,[QD<9F'",J<Z\Y)58U/8JI3Q5'+IM2A2C
M[6I@XNNJ5%XNE6E2C)?U<^-</6E3QF+R>C6S2C%1HXJ$HQA!>ZFY1UJI/WO=
MC/3F:3U=_*_@GX&U#P/X4E@UB**#5M6OY=2NH(7$BVJ"&.WM+=I%;89E@1I+
MD+YB"YN)5C<QHE?-_P"TL"?B);.%8HOAG3LE5+8V7FM,P.`3G:RD#&6!^7/-
M?>?'````XQT&.F>HZ>G7W/`J%[6"9B\D2,0=GS(C''!&6920`20!T'3KT_9^
M._H]Y/Q3X-9)X.9#F];(\JR&OE57!8_%4(X[$UUECQ<JU3$PA]4B\3CL3C:N
M)Q%2$(0]M.;A",&DO"P'$-?"YW6SJO0CB*M=5E*E";IJ/MG322YW.2C",%&*
MO)I63[G)?#P?\4'X,C8$.GA30`RNI5E*Z99ALA@.F<$_A7\UG_!Q)\"3=77P
M#^/NAZ-<37]W!K_P@\7W=I:2W+7%I:B3QAX%\]+='V+:33^.K<S7"B-VU"UM
M_-5A%')_4/'$L:`(,`(%"\``8``PH4<``#V&!BJ=W965\`MY;6]V(V698YHH
MI0DD8*AP'5BI&6&X?,%9E#!6(K^BN"?:<)8;),-&4<7/)\JP6`G+E=.&*A@\
M!0P4ZG*VW"-3E]HJ;E*4'*#O=7/QWQ8X%P7BCP?GO"F-Q+R]9Q5H8BACHTHU
MYX'&8;'T<PH5Z=.4X<]JE%TIPYXN=&I4I\WOL_F*_P"#=SX%M"_[07[0.MZ+
M<6VH?\4U\*O!]]>6;VMPEG*I\5^-FM'N%0RVU[-'X*B:6W/D,^FSQAY'#*G[
MR?ML)(W[&_[5J!)))'_9T^-,<<<:/-+)(_P[\0I%%%%&'DFFE=@D442-++(R
MQHC.RJ?I6QL+2PB:.SMH+:.1O,:.WABA0L0!N*Q*BDE0!G&<`#H!B>XBBGAE
MAG1)8)4*31R*KQR1MPZ.C@JR.I*L&&"I->YF&93S',GF%2FH-SI.-*#?+"-*
M-."C%N]KJFFW;63;:=SSN`/#7`^'_AQA^`,#C7B(4<%FM&OFLZ"A/$XG-:V*
MKUL74H1J*_LWB(TX4W5NJ%&G24XI*W\8_P#P0#T_4+/]N+Q+/=Z=J-K`_P"S
MG\0(%GN-/O(8C-/XZ^&LT,7F20J@DEBBEEC0L&>.*1U!5'(_5?\`X+R_LU_$
M/XU_L_?#?XD?#KPO>^+-1^!WBKQ#JOBG3M+C%SK%MX#\3:3:0:QK&G:?%YEY
MJS:?J6@Z`]Y86$<ETNGRW-^MM*EA(8_W0MM&TNSD\^VLK.WD*%3)#:V\+,K!
M`58Q(AQ^[1L?=W`-C(%76@C>-HY2LBL-I#!"""<D$%<$>QSGD=Z[JN?UJN<4
M,XC1A"K0=*]*\G":IKDM?25I1DU+6^J:LM#XSAWP%RC)O"+-O"+&YUBLQR[-
MJV.KSS:&&H8:OAJV*Q.%QF'J0H3G6A.6&Q&$HU(75I6E&2U3C_&=_P`$\O\`
M@J1^TS\,?A/I/['WP;_9[M_V@O&VFZGXA?X;75KKVKVUWX4TO7M2O-3U"S\5
M:%8:/?+<:)H>OZG>7S:E>:[X6L].T^=['4K^SM[:&2OF?_@GUX8\:^%_^"GW
MP4TCQQIL\7B31/CQXQTOQ1>VUI=#1Y==TZ+Q99:Q=:?.]M`ITV?5(Y7LY]D4
M4L$UJ$2,21*W]U&E^#/"6@W%W=Z+X=T32+J]<SWMWIFF6-C<7,I8L6GDMH8F
ME)/)WELL2S?,23I#1M*2=)H--L(Y=S3F9+.V\WS=Q8OO\HN)&9RQ8$$MU)Y!
MZJO$F&MF'U;*Z6%>84JD<14]O*51SJ1DI2;LH67.Y<D()2EK)R]VWQV&^C;G
M%>/AXN(_$[-,^I^&^=Y=C<AP<LFP>&P%'*\OQ.#KX?`1A"H\34K5?J=##5,;
MBL76A##T:4*.'I6FZG\V_P#P<*_`KXH^--/^!7QF\)>&=6\1^!OAUI7C_P`.
M>.;K2H9+R;PN?$U_X5O]+U6\LH8Y+F+1[R+0]0MK_4EB-O9S0VZ7\L$=Q;%O
MD']BW_@K)^TMH/P*\$?L>_`']G#3/BU\2_#NG:AX3\"^+M&U+5+N+3[34+RZ
MGTO5_%'A33])-@6T&?4$6_U+4?%^AZ3<I;G4=7O+%)KEX_[#+BQM;R*XMKZ*
M.YMKE72:WN8DD@DCD#!XWCD0AT;(W(<JVWD$%A6-H_@GPAX=2;_A'_#>AZ*;
MG>9FTO3+*PDD,GWV,EK%"V]N<L#NSR#NYKFPF>X>GE]'+\5E]''4L-5=;#N5
M6I32G-N3=51?[Q7DXI)TUR_$I-IKZ3B#P,SS%>)6=>(G"GB)F?!V(XGRW#9=
MQ#@\)EF`S#$UJ.'HX/"I9?B<5STL&Y4<OPM2,YX;$UH5Y5ITJL(5%2C_``M?
ML-Z-\0_#O_!4/X01?%JTU"W^(-A^T1XB@^(EQ>PV[N_C:2Y\1P^)+B6?2HET
MJ=;OQ!)=R1W>EC^RKH3)<:>S64L+'^\V,@[@#R"N1W'R+P1V/L:S(]&TI9?M
M']G6*W1E,WV@6L`G$Q8DR^:5\PR%LG?G=GGKFM..,)DY))"@Y/`"YP,#C//)
MZGC).*Y<ZS7^V,31Q'L%A_8X=8?D4N:+2DYWCI'E2<N6,=;125WN?6>#/A/2
M\(<FSS)J&>8OB"&=<08C/7C,=AX4,72]OA,)AO8XB4*M18BN_JL:M6NHTE4G
M4F_9QT2DHHHKQS]B.>\27&J)X;UZ;0X%N-:BT;4I='MY615FU..TE:PA<N-@
M66[6)26RNTDMQFOPB^$7_!97]CK2]*TS6?CGX;\9_#7]HCP[X/TOP!\2HIO`
MHO=0FU#P^=NJ:9;:K9W*W4^G1^(%O[JTLM2CAF@:YV@,)/.;]^V16!4YP003
MG!P3GK[8X]*\5UC]FSX!>(?$I\8ZY\'_`(>ZMXI:9+EM?O\`POI5QJ;W"/YB
MSO=26QD>429D+L2Q<EB2>:[<+6PE.,X8K#U:BERN,Z%94:L>56<.:4*D'">\
MKP<KI6:U3^`XRR;CG'ULMQ?!6?Y#E-;#.O3QN%XDR6OG>7XBG5G2J4L10A@\
M=EN+P^/PDH5(4:D,6J-2E7J1K4I-4Y0_*N7_`(*G?%#X^FX\+?L,_LG_`!/\
M?:[J"H^G_$7XI:<W@OX:Z1:WC"VBUBZFGN-FJ06GFI=_8+#57GFB3S(K251(
MBL\'?\$W/C]^T;XLB^)?_!17X\7WC^W@;3[G1O@-\,]2U#P]\+](DMI':>'4
M_L@T]M:M9MD<4UK'8V/VL?:DU.?5()]J_MA8Z)I&F0I;Z;IMEI\$>`D-C;0V
MD2@;,*J0)&H&44D8_G6@(D&.IP-HR>@SGMCOS6\LQIT5-9=A:>$<DXNM-_6,
M4XV2:]O-)4[J]W1ITWJTVT[+R*?AK7SJIA\1XB\2YEQE/#5(UJ.3THPR'A*E
M63YN:ID6`G[3-8QG9PCG^89K2IRITYTJ,*J=0X+1_AKX#\/Z%IWAC1_"/A_3
M?#VDP16VEZ-8:79VVGV-O%&L<<,-K%$L")&J*%VH#@G<6)R+H\"^#AT\,:%_
MX++7/X_(*[+8OIGZ]^W/M[=*4*H[#\J^,Q_"W#F;8F6,S;(,CS+%SA&$\3CL
MHP&,Q,E#2,77Q%"I4<8IM)-_<?KE#$XC"T*>&PM:MA\/22C3H4:U2C1IP5O=
MA2I.,(I6LDDM'8P])\/:+HS3OI&E6&FM.J+,UC:Q6QE";_+\SRE'F&,R.8]W
MW=[XQN-;@&`!UP`,_2EP!T`%%>I@<!@<LPM+`Y=@\+@,%0Y_8X3!X>CA<-2]
MK4G6J>SH4(4Z5/GJU*E2?)!<]2<IRO*4FXG4JU9.I6G.I4DES3G.524N5**O
M.;<G9))7>B22T2"BBBNL@YSQ/X:T'Q?H^H>'/$^C:;X@T#5H#:ZIHVKV=M?Z
M;J%L2CF"\L[J.2&XB+(K;)%9<J#C(&.2^'_P>^%WPQNM1O/A]\//!?@BYU>W
MM[;4YO"OA[3M%EOX+666:VANWL;>$W$=O+<3R1"0L%:9F`!)KT_`]!^5+0IU
M-8W]Q[KF>MK-76V_Y(PGA<-.M#$3P]&>(I7]E7G2I2JT[IQ?LZDJ;J4[IR3Y
M)JZDTVTV@HHHH-PHHHH`****`"C`]/;\/2BB@`HHHH`****`"BBB@`HHHH`*
****`"BBB@#__V3\_
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
